Navigation Links
Nile Therapeutics, Inc. to Present at Upcoming BIO CEO & Investor Conference
Date:2/5/2008

BERKELEY, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: NILT), announced today that Peter M. Strumph, Chief Executive Officer, will present at the BIO CEO & Investor Conference at the Waldorf-Astoria Hotel in New York City on Tuesday, February 12, 2008 at 11:00 a.m. EST. Mr. Strumph will provide an overview of Nile and an update on its clinical development programs.

The presentation will be webcast live and can be accessed by visiting the Investor Relations section at http://www.nilethera.com. The webcast will be archived for ninety days. Additional information regarding the BIO Investor Forum can be accessed at http://ceo.bio.org.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel chimeric peptide in Phase I studies for the treatment of acute decompensated heart failure, and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties. A key component of the Company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

Contact:

Daron Evans

Chief Financial Officer

Nile Therapeutics, Inc.

510-281-7700

info@nilethera.com

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of histor
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
2. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
3. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
4. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
5. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
6. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
7. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
8. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
9. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
10. Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
11. Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary commercial focus on ... granted a Type C meeting with the U.S. Food ... be held in February 2015.  During this meeting the ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 METTLER ... inline PVM tool, ParticleView V19 with PVM ... situ probe-based particle vision and measurement tool continuously ... process conditions. ParticleView V19 then automatically prepares a ... tracking particle size and concentration changes. This compelling ...
(Date:12/15/2014)... 2014  GlassesOff Inc. (OTCBB: GLSO) announced today the ... independent director of the Company,s Board of Directors. ... as its CEO until its acquisition by Stanley ... transaction. Recognized as the inventor of the first Wi-Fi-based ... Wi-Fi -based RFID solutions focused on improving operational efficiency, ...
(Date:12/13/2014)... CanDiag, Inc., a University of North Carolina at ... to OncoTab, Inc. , “The new name is ... said CEO and Chief Science Officer, Dr. Pinku Mukherjee, ... diagnostics to include imaging and therapies, and our new ... in 2011 by Dr. Mukherjee, an Irwin Belk Endowed ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc. 2
... Uroplasty, Inc. (NASDAQ: UPI ), a ... proprietary products to treat voiding dysfunctions, announced today that ... President and CFO, will present the Company,s business strategy ... Conference at 2:10 PM ET on Tuesday, December 13, ...
... Conn., Dec. 6, 2011 Biodel Inc. (Nasdaq: ... ended September 30, 2011. Fourth Quarter Operating ... 2011, the company: Selected a new lead ... a Phase 1 clinical trial; Extended an agreement with ...
... Pharmaceuticals, Inc. (NASDAQ:   QCOR) announced today that executive ... be held on December 13-14, 2011 in New York.  ... scheduled to present an overview of the Company on ... A live webcast and subsequent archived replay ...
Cached Biology Technology:Uroplasty to Present at the Oppenheimer 22nd Annual Healthcare Conference 2Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results 2Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results 3Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results 4Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results 5Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results 6Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011 2
(Date:12/4/2014)... GARDENS, Fla. , Dec. 3, 2014 /PRNewswire/ ... solutions, today announced that its DigitalPersona ® ... fingerprint readers have been deployed throughout First Bank ... , South Carolina and ... in Southern Pines, North Carolina ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014 Strict ... driver efficiency are piloting the North American and European ... of accidents growing, gesture recognition systems that are intuitive ... a mark in the industry. New ... Automotive Gesture Recognition Market in Europe ...
(Date:11/18/2014)... BETHESDA, Md. , Nov. 17, 2014 The ... European and U.S. regulatory agencies will speak and at least ... Quality Metrics Conference at the Omni Shoreham Hotel in ... is pleased once again to have significant support from the ... and Europe in our effort to ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... may one day reap the benefits of research at the ... can be used to make new tendon or ligament tissue. ... challenge to orthopedic medicine. In the United States, at ... Moreover, the intervertebral disc, which is composed in part of ...
... activity of a key brain cell receptor involved in ... mice engineered to have pathological hallmarks of the disease. ... the pathologies--the brain-clogging buildup of protein "amyloid plaque" outside ... cells. , In an article in the March ...
... to neural stem cells derived from bone marrow, researchers ... developed a tool to track and kill malignant brain ... , Results of an animal study are published in ... the researchers are now applying to regulatory agencies to ...
Cached Biology News:Stem cells can repair torn tendons or ligaments 2Experimental drug reverses key cognitive deficits, pathology in Alzheimer's 2Marrow-derived stem cells deliver new cytokine to kill brain tumor cells, offer protection 2Marrow-derived stem cells deliver new cytokine to kill brain tumor cells, offer protection 3
Alkali soluble casein is the recommended blot blocking reagent for use with the HisTag Monoclonal Antibody (Novagen) on Western blots....
Phospho-Btk (Tyr223) Antibody...
Goat polyclonal to Dysadherin ( Abpromise for all tested applications). entrezGeneID: 53827...
UBC13 Antibody...
Biology Products: